GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ImmunityBio Inc (FRA:26CA) » Definitions » Sale Of Investment

ImmunityBio (FRA:26CA) Sale Of Investment : €125.30 Mil (TTM As of Dec. 2024)


View and export this data going back to 2021. Start your Free Trial

What is ImmunityBio Sale Of Investment?

ImmunityBio's sale of investment for the three months ended in Dec. 2024 was €17.22 Mil. It means ImmunityBio gained €17.22 Mil from selling investments. ImmunityBio's sale of investment for the trailing twelve months (TTM) ended in Dec. 2024 was €125.30 Mil.

Compared with last quarter (€62.68 Mil in Sep. 2024 ), ImmunityBio gained less money from selling investments in Dec. 2024 (€17.22 Mil).


ImmunityBio Sale Of Investment Historical Data

The historical data trend for ImmunityBio's Sale Of Investment can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ImmunityBio Sale Of Investment Chart

ImmunityBio Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Sale Of Investment
Get a 7-Day Free Trial 60.52 61.89 152.93 9.60 130.46

ImmunityBio Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Sale Of Investment Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 12.88 32.52 62.68 17.22

ImmunityBio Sale Of Investment Calculation

Sale of Investments represents cash inflow on the sale of investments in securities.

Sale Of Investment for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €125.30 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


ImmunityBio Sale Of Investment Related Terms

Thank you for viewing the detailed overview of ImmunityBio's Sale Of Investment provided by GuruFocus.com. Please click on the following links to see related term pages.


ImmunityBio Business Description

Traded in Other Exchanges
Address
3530 John Hopkins Court, San Diego, CA, USA, 92121
ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: the United States and Europe. Key revenue is generated from the United States.

ImmunityBio Headlines

No Headlines